Sertraline: Hot Flashes (Men)

Generali, Joyce; Cada, Dennis J.
November 2007
Hospital Pharmacy;Nov2007, Vol. 42 Issue 11, p1020
Academic Journal
The article discusses a study on hot flashes in prostate cancer survivors. Elderly men receiving antiandrogen therapy for prostate cancer were given sertraline for psychiatric symptoms. The product labeling for antidepressants was revised to include a black box warning regarding a possible increased risk of suicidal thinking and behavior. It suggests that sertraline may have beneficial effects in reducing the frequency and severity of hot flashes in prostate cancer patients.


Related Articles

  • Antiandrogens increase risk of dementia.  // Reactions Weekly;10/29/2016, Vol. 1625 Issue 1, p8 

    The article presents the study which examines the risk for dementia with antiandrogens in patients with prostate cancer.

  • PCa patients benefit from intermittent androgen suppression. Perry, Wes // Urology Times;May98, Vol. 26 Issue 5, p22 

    Discusses benefits of prostate cancer patients receiving intermittent androgen suppression treatment. Details on the treatment; Development of androgen-dependent progression; Other advantages of the treatment.

  • Intermittent Androgen Suppression Controls PCa. Troxel, Scott // Urology Times;Feb2000, Vol. 28 Issue 2, p13 

    Reports on the efficacy of intermittent androgen suppression in the control of prostate cancer in patients. Presentation of findings by research team led by professor S. Larry Goldenberg; Treatment cycle of patients.

  • Role of maximum androgen blockade in advanced prostate cancer. Ayyathurai, Rajinikanth; De Los Santos, Rosely; Manoharan, Murugesan // Indian Journal of Urology;Jan2009, Vol. 25 Issue 1, p47 

    Androgen ablation is the mainstay treatment for advanced prostate cancer (PC). Researchers proposed that maximum androgen blockade (MAB) therapy with antiandrogen agent in combination with castration might result in a better outcome among patients with advanced PC. In the last two decades,...

  • Radiotherapy plus hormone therapy halved prostate cancer mortality.  // Hem/Onc Today;3/10/2014, Vol. 15 Issue 5, p24 

    The article discusses research being done on the addition of radiation therapy to anti-androgen therapy for patients with prostate cancer, which references a study by Sophie Dorothea Fosså et al. presented at the 2014 Genitourinary Cancers Symposium in San Francisco, California.

  • Androgen deprivation therapy linked to metabolic syndrome.  // Reactions Weekly;9/9/2006, Issue 1118, p3 

    The article discusses research being done on the effect of long-term androgen deprivation therapy (ADT) in men with prostate cancer. It references a study by M. Braga-Basaria et al published in the August 2006 issue of "Journal of Clinical Oncology." The study revealed that the prevalence of...

  • New findings could lower risk of suicide in men with prostate cancer.  // Biomedical Market Newsletter;11/9/2011, Vol. 21, p790 

    The article reports on the findings of a study conducted by researchers at the University of Gothenburg's Sahlgrenska Academy in Sweden that show that communicating negative intrusive thoughts could lower the risk of suicide in men with prostate cancer. It reveals that 73% of the 833 men...

  • Comparison of efficacy and safety of 1- and 3-month luteinizing hormone-releasing hormone agonist depots as initial therapies for prostate cancer. Ishizuka, Osamu; Nishizawa, Osamu; Nishizawa, Shuji; Satoh, Tomoya; Wajiki, Masahisa; Kiyokawa, Hideo; Inoue, Yoshihiro; Kobayashi, Shinya; Mizusawa, Hiroya; Nakagawa, Tatsuo // International Journal of Clinical Oncology;Jun2013, Vol. 18 Issue 3, p524 

    Background: We compared the efficacy and safety of 1- and 3-month depots of the luteinizing hormone-releasing hormone (LH-RH) agonist goserelin acetate in prostate cancer patients. Methods: Patients were randomly assigned to the Direct Group that received the goserelin 3-month depot or the...

  • Prior administration of a non-steroidal anti-androgen failed to prevent the flare-up caused by a luteinizing hormone-releasing hormone agonist in a patient with metastatic prostate cancer. Sho Uehara; Takeshi Yuasa; Yasuhisa Fujii; Akihiro Yano; Shinya Yamamoto; Hitoshi Masuda; Iwao Fukui; Junji Yonese // BMC Research Notes;Aug2015, Vol. 8 Issue 1, p1 

    Background: 'Flare phenomenon' after initial luteinizing hormone-releasing hormone agonist administration is a widely approved concept in the treatment of prostate cancer. In most guidelines, concomitant therapy with antiandrogens is recommended to prevent this flare phenomenon. However, there...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics